Age-Related Variations in Treatment Patterns for Axial Spondyloarthritis

Year 2024, Volume: 6 Issue: 3, 324 - 328, 24.09.2024

Esra Kayacan Erdoğan , Kevser Orhan , Rezan Koçak Ulucaköy , Bahar Özdemir , Serdar Can Güven , Ebru Atalar , Berkan Armağan , Hakan Babaoglu

https://doi.org/10.37990/medr.1481080

Abstract

Aim: This study examines treatment patterns and preferences among patients diagnosed with Axial Spondyloarthritis (AxSpA) across different age groups.
Material and Method: Ankara Bilkent City Hospital registry enabled a comprehensive cross-sectional analysis of 2,811 patients stratified into three age groups: 18-40, 41-55, and over 55 years. These groups were compared in terms of their treatments.
Results: Our findings indicate an increasing prevalence of female patients and comorbidities with age. Medication usage patterns showed a trend towards increased use of Methotrexate and Colchicine with age, while Sulfasalazine and Leflunomide were more commonly prescribed in older age groups. Notably, the use of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs), including anti-Tumor Necrosis Factor (anti-TNF)", "anti-Interleukin (anti-IL) agents, demonstrated a declining trend with advancing age, though not reaching statistical significance. This trend was also reflected in gender-specific treatment distributions, where no significant difference was found in bDMARDs administration among patients over 55 years, contrasting with a higher usage rate in younger male patients.
Conclusion: Our study highlights a shift towards more conservative treatment approaches, such as increased conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) use in older patients, likely due to their safety profile and the specific challenges associated with treating older adults, including higher comorbidity rates and medication side effects. These findings emphasize the need for personalized treatment strategies and suggest potential adjustments in clinical practices to better accommodate the aging population, advocating for ongoing research to optimize treatment efficacy and safety for elderly patients with AxSpA.

Keywords

Axial spondyloarthritis, elderly, antiTNF, antirheumatic agents

References

• Sepriano A, Ramiro S, van der Heijde D, et al. What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Ann Rheum Dis. 2020;79:324-31. Erratum in: Ann Rheum Dis. 2020;79:e78.
• van der Heijde D, Molto A, Ramiro S, et al Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis. 2024;83:547-9.
• Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447.
• Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol. 2008;35:305-9.
• Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20:35.
• Bandinelli F, Martinelli-Consumi B, Manetti M, Vallecoccia MS. Sex bias in diagnostic delay: are axial spondyloarthritis and ankylosing spondylitis still phantom diseases in women? a systematic review and meta-analysis. J Pers Med. 2024;14:91.
• Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008;58:929-38.
• Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18:205-16.
• Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2004-12.
• Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66:419-21.
• Ma Z, Liu X, Xu X, et al. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine. 2017;96:e7145.
• Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis?. Rheumatology. 2002;41:1330-2.
• Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol. 2004;31:1568-74.
• Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014;2014:CD004800.
• Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
• Khanna Sharma S, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis. 2018;21:308-14.
• Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995;38:618-27.
• Nissilä M, Lehtinen K, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 1988;31:1111-6.
• Krajnc I. Sulphasalazine in the treatment of ankylosing spondylitis [Serbocroatian]. Lijec Vjesn. 1990;112:171-4.
• Bayrak ED, Aktas I. Identifying clinical features, frailty, and treatment responses of late-onset axial spondyloarthritis. Indian Journal of Rheumatology. 2023;18:266-71.
• Toussirot, É., Wendling, D. Late-onset ankylosing spondylitis and related spondylarthropathies. Drugs Aging. 2005;22:451-69.
• Harrison MJ, Kim CA, Silverberg M, Paget SA. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis?. J Rheumatol. 2005;32:1243-8.
• Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003;30:691-6.
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med. 2001;345:1098-104.
• Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018;20:35.